213 results on '"Hovinga, J"'
Search Results
2. PB0313 Towards the Standardisation of ADAMTS-13 Antibody Testing in Thrombotic Thrombocytopenic Purpura (TTP)-Results of the IMATAS Collaborative Study
3. OC 26.1 Transient Ischemic Attacks (TIAs) and Ischemic Strokes are Leading Events in Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)
4. PB0345 Diagnosing Heparin-Induced Thrombocytopenia: A Prospective Multicentre Study
5. PB1265 “HERMES” - HEmophilia Related MEntal illnesS: A Cross-Sectional, Multicenter Study in Switzerland
6. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
7. Effectiveness of emicizumab under real-world conditions in patients of all ages with hemophilia A with and without FVIII inhibitors: Third interim analysis of the non-interventional study EMIIL.
8. Daratumumab for Refractory and Frequently Relapsing Immune Thrombotic Thrombocytopenic Purpura – a Case Series with Long-Term Follow-up.
9. Clinical and Functional Assessment of Elderly Patients with Haemophilia.
10. Komplexe Gerinnungsstörungen
11. S294: LONG-TERM SAFETY AND EFFICACY OF CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP): THE POST-HERCULES STUDY
12. The dynamic range of immunoassays for heparin-induced thrombocytopenia.
13. High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence
14. Hereditary afibrinogenemia - long-term observation of a highly thrombogenic condition and itʼs management: OR432
15. The predictive value of ADAMTS13 activity for treatment monitoring of patients with acquired TTP: data from the phase II TITAN trial with caplacizumab: OR363
16. Hereditary TTP - a young patient population with high prevalence of arterial thromboembolic events: first results from the hereditary TTP registry: OR152
17. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH
18. Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies
19. Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors
20. Upregulated autophagy in antigen-presenting splenic cells hints at promotion of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
21. Humoral immune response to ADAMTS13 in acquired thrombotic thrombocytopenic purpura
22. Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies
23. Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura
24. Safety of caplacizumab in patients without documented severe adamts13 deficiency during the hercules study
25. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura
26. VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura
27. Die erbliche Form der thrombotisch thrombozytopenischen Purpura (TTP) – selten, aber bei Schwangerschaftskomplikationen zu bedenken!
28. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13)
29. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock
30. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies
31. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura
32. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods
33. A new tool to further explore the role of ADAMTS-13 in health and disease
34. Treatment of thrombotic thrombocytopenic purpura
35. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13
36. Thrombotic thrombocytopenic purpura
37. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency
38. A functional single nucleotide polymorphism in the thrombin‐activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease
39. Soluble thrombomodulin in patients with established atherosclerosis
40. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease
41. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease
42. Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura
43. Résultats d’efficacité d’une analyse intégrée des essais cliniques de phase 2 et 3 évaluant caplacizumab dans le purpura thrombotique thrombocytopénique acquis
44. Pregnancy Outcomes in Hereditary Thrombotic Thrombocytopenic Purpura – Room for (Further) Improvement.
45. Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary cohort of patients.
46. Fulminant Essential Thrombocythemia Associated with Acquired Von Willebrand Syndrome and Bleeding Episodes in a 14-year-old Girl
47. Résultats de l’essai de phase III HERCULES – Essai contrôlé randomisé en double aveugle du caplacizumab dans le traitement du purpura thrombotique thrombocytopénique acquis
48. Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab.
49. The european hematology association roadmap for european hematology research: A consensus document
50. T-12-09: Biobanking for testing hemostasis: Longterm stability of citrated plasma samples.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.